NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PSNL Stock Alerts $1.63 -0.02 (-1.21%) (As of 10:27 AM ET) Add Compare Share Share Today's Range$1.61▼$1.6950-Day Range$1.20▼$1.7552-Week Range$0.89▼$2.60Volume28,548 shsAverage Volume357,337 shsMarket Capitalization$82.32 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Personalis alerts: Email Address Personalis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside203.0% Upside$5.00 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.69Based on 15 Articles This WeekInsider TradingSelling Shares$6,197 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.58) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector84th out of 915 stocksMedical Laboratories Industry4th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 2 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.62% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently decreased by 0.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 3.2 News and Social Media Coverage News SentimentPersonalis has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Personalis this week, compared to 1 article on an average week.Search Interest5 people have searched for PSNL on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,197.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.58) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Personalis Stock (NASDAQ:PSNL)Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More PSNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSNL Stock News HeadlinesMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amid Strong Financial Performance and Strategic Growth ProspectsMay 9, 2024 | markets.businessinsider.com4 Analysts Have This To Say About PersonalisMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 9, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comPersonalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comIs Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?May 9, 2024 | finance.yahoo.comPersonalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...May 8, 2024 | investorplace.comPSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 8, 2024 | finance.yahoo.comPersonalis Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comPersonalis is about to announce its earnings — here's what to expectMay 7, 2024 | americanbankingnews.comPersonalis (PSNL) Set to Announce Quarterly Earnings on WednesdayMay 2, 2024 | msn.comLake Street Initiates Coverage of Personalis (PSNL) with Buy RecommendationMay 1, 2024 | americanbankingnews.comPersonalis (NASDAQ:PSNL) Coverage Initiated by Analysts at Lake Street CapitalApril 24, 2024 | businesswire.comPersonalis to Announce First Quarter 2024 Financial ResultsApril 2, 2024 | investing.comCathie Wood's ARK makes major moves in Tesla stock, sells RobinhoodMarch 29, 2024 | investing.comCathie Wood's ARK buys over $14M in Tesla stock, sells Coinbase in latest tradesMarch 28, 2024 | businesswire.comPersonalis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | businesswire.comData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 26, 2024 | finance.yahoo.comPersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response MonitoringMarch 19, 2024 | businesswire.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | finance.yahoo.comPSNL Apr 2024 2.500 putMarch 6, 2024 | finance.yahoo.comPSNL Apr 2024 7.500 callMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Personalis’s Strategic Advances and Financial Health Signal Promising Growth in 2024March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth ProspectsMarch 1, 2024 | seekingalpha.comPersonalis, Inc. (PSNL) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | uk.finance.yahoo.comPersonalis, Inc. (PSNL)See More Headlines Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees223Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$7.50 Low Stock Price Target$3.50 Potential Upside/Downside+203.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-147.38% Pretax Margin-147.27% Return on Equity-61.42% Return on Assets-41.05% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio2.88 Sales & Book Value Annual Sales$73.48 million Price / Sales1.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.63Miscellaneous Outstanding Shares50,504,000Free Float48,433,000Market Cap$83.33 million OptionableOptionable Beta1.91 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christopher M. Hall (Age 55)President, CEO & Director Comp: $963.75kMr. Aaron L. Tachibana (Age 63)CFO & COO Comp: $811kMr. Stephen M. Moore J.D. (Age 52)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $597.98kDr. Richard Chen M.D. (Age 53)M.S., Executive VP of R&D and Chief Medical Officer Comp: $800.6kDr. Russ B. Altman M.D.Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Euan A. Ashley DPHIL (Age 53)FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Michael J FitzpatrickVice President of Worldwide SalesDr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Laboratory OperationsMr. Stephane Mouradian Ph.D.Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZExagenNASDAQ:XGNDermTechNASDAQ:DMTKBiodesixNASDAQ:BDSXSera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsHowland Capital Management LLCBought 168,274 shares on 5/4/2024Ownership: 0.418%Nikko Asset Management Americas Inc.Sold 106,051 shares on 5/3/2024Ownership: 1.936%Wellington Shields Capital Management LLCSold 40,900 shares on 5/3/2024Ownership: 0.865%GSA Capital Partners LLPBought 24,498 shares on 5/3/2024Ownership: 0.832%Stephen Michael MooreSold 4,523 sharesTotal: $6,196.51 ($1.37/share)View All Insider TransactionsView All Institutional Transactions PSNL Stock Analysis - Frequently Asked Questions Should I buy or sell Personalis stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks. What is Personalis' stock price target for 2024? 3 Wall Street analysts have issued 12 month target prices for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts. How have PSNL shares performed in 2024? Personalis' stock was trading at $2.10 at the start of the year. Since then, PSNL stock has decreased by 21.4% and is now trading at $1.65. View the best growth stocks for 2024 here. When is Personalis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PSNL earnings forecast. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) posted its earnings results on Wednesday, February, 28th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company earned $19.68 million during the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 61.42%. What ETF holds Personalis' stock? ARK Genomic Revolution ETF holds 6,542,887 shares of PSNL stock, representing 0.73% of its portfolio. What guidance has Personalis issued on next quarter's earnings? Personalis updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.5 million-$20.5 million, compared to the consensus revenue estimate of $18.4 million. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and When did Personalis IPO? Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Personalis' stock is owned by many different retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (1.94%), Sumitomo Mitsui Trust Holdings Inc. (1.94%), State of Michigan Retirement System (0.98%), Wellington Shields Capital Management LLC (0.87%), GSA Capital Partners LLP (0.83%) and Howland Capital Management LLC (0.42%). Insiders that own company stock include Aaron Tachibana, Christopher M Hall, John Stephen West, Lightspeed Venture Partners Se, Richard Chen and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSNL) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.